Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lab21's portfolio swells with new tests from deCODE

This article was originally published in Clinica

Executive Summary

UK diagnostics firm Lab21 and Icelandic biopharmaceutical company deCODE genetics have struck up a deal to make the latter’s DNA-based tests available in the UK and Ireland. Lab21 will now distribute deCODE’s CE-marked and FDA-approved tests for genetic predisposition of type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer and glaucoma. This deal also allows Cambridge-based Lab21 to offer new tests as they emerge from deCODE’s pipeline, including one for the increased risk of oestrogen-positive breast cancer. Financial details of the deal were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel